Clinical Trials Logo

Filter by:
NCT ID: NCT05266885 Completed - Clinical trials for Prevalence of Elevated Blood Pressure in Type-2 Diabetics

Prevalence of Hypertension in Type-2 Diabetes Mellitus

Start date: November 1, 2019
Phase:
Study type: Observational

Cardiovascular disease is the most prevalent cause of morbidity and mortality in diabetic patients. Hypertension has been confirmed as a major risk factor for cardiovascular disease, which is frequently associated with diabetes mellitus. Therefore, the detection and management of elevated blood pressure (BP) is a critical component of the comprehensive clinical management of diabetics. Since the rates of hypertension in diabetics are lacking in Afghanistan, this study aimed to evaluate the prevalence of elevated blood pressure in type-2 diabetic patients.

NCT ID: NCT05251350 Completed - Clinical trials for Incarcerated Inguinal Hernia

Incarcerated Right Inguinal Hernia Containing Sigmoid Colon: An Unusual Case Report

Start date: September 10, 2021
Phase:
Study type: Observational

Incarcerated inguinal hernia is an irreducible but the blood supply to the contained part is intact, but developing towards strangulation. Here the lumen of the portion of colon occupying a hernia sac is blocked with faeces.

NCT ID: NCT05228977 Completed - Clinical trials for Prevalence of Cervical Extension of the Thymus

Prevalence of Cervical Extension of the Thymus in Children

CET
Start date: August 1, 2018
Phase:
Study type: Observational

This prospective, observational study included all pediatric patients who were referred to the radiology department for neck ultrasonography between August-October 2018. A high-frequency probe was implemented and 220 patients were examined.

NCT ID: NCT05088200 Completed - Clinical trials for The Study Was Aimed to Assessing the Clinical Profile of Acute Abdomen and Their Frequency According to Age and Sex

A Retrospective Case Series Study for Acute Abdomen in General Surgery Ward

Start date: March 21, 2018
Phase:
Study type: Observational

The acute abdomen is a clinical situation in which an acute an change in the condition of intra-abdominal organ, commonly attached to inflammation or infection need urgent and correct diagnosis .

NCT ID: NCT04581993 Recruiting - Stunting Clinical Trials

Effectiveness of SNF and SBCC to Prevent Stunting Among Children in Afghanistan: a Quasi-experimental Study

Start date: February 1, 2021
Phase: N/A
Study type: Interventional

Over the years, there has been some progress made in reducing stunting in Afghanistan, the prevalence remains high with half of the provinces experiencing rates above the WHO alert threshold. As part of the Country Strategic Plan (CSP), the World Food Programme (WFP) plans to implement a stunting prevention programme in collaboration with Ministry of Public Health (MoPH) through its Public Nutrition Department (PND) in selected locations with stunting rates above 45%. The programme will emphasis on appropriate nutrition support in the '1000 days' window of opportunity with special focus on proven effective nutrition interventions such appropriate breast feeding, complementary feeding, micronutrient supplementation, malnutrition treatment and prevention, WASH.

NCT ID: NCT04498949 Completed - Anxiety Clinical Trials

Transdiagnostic Treatment for Emotional Disorders

UP
Start date: August 15, 2020
Phase: N/A
Study type: Interventional

Background and study aims Depression is more prevalent in younger populations. The age of first onset of depression has become younger, yet many adolescents with depressive symptoms remain untreated. Rates of anxiety and depression are increasing among children and young people.postsecondary education also represents a peak onset period for the occurrence of mental disorders. It is estimated that 12-46% of all university students are affected by mental health disorders in any given year. Who can participate? Afghan students over 18 years old fluent in Persian or Pashto, and access to an internet connection. What does the study involve? Participants will be randomly allocated to receive training in skills and coping strategies which are useful in stressful conditions.

NCT ID: NCT04360486 No longer available - Clinical trials for Severe Acute Respiratory Syndrome Coronavirus 2

Treatment Of CORONAVIRUS DISEASE 2019 (COVID-19) With Anti-Sars-CoV-2 Convalescent Plasma (ASCoV2CP)

Start date: n/a
Phase:
Study type: Expanded Access

This treatment protocol is designed to provide convalescent plasma as a therapeutic option for patients diagnosed with and hospitalized for COVID-19 with symptoms ranging from mild to life-threatening.

NCT ID: NCT04302766 No longer available - Clinical trials for Coronavirus Disease 2019

Expanded Access Remdesivir (RDV; GS-5734â„¢)

Start date: n/a
Phase:
Study type: Expanded Access

Disease caused by 2019 Novel Coronavirus also known as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)

NCT ID: NCT04133766 Terminated - Nutrition Clinical Trials

Community-based Nutrition Program Effectiveness Evaluation in Afghanistan

Start date: November 1, 2019
Phase: N/A
Study type: Interventional

The study will be a mixed methods, two-arm, cluster-randomized controlled trial. The primary aim of this evaluation is to measure the effectiveness of the Community-Based Nutrition Package intervention on child feeding practices among parents/caregivers to children 6 to 23 months of age in Afghanistan.

NCT ID: NCT02876549 Completed - Vivax Malaria Clinical Trials

G6PD Assessment Before Primaquine for Radical Treatment of Vivax Malaria

GAP
Start date: September 1, 2016
Phase: Phase 4
Study type: Interventional

This will be a single-arm observational cohort study. Malaria patients with Plasmodium vivax and meeting study inclusion criteria, who give consent to be enrolled in the study, will have their G6PD status measured by the CareStartâ„¢ G6DP rapid diagnostic test (G6PD RDT), and primaquine prescribed according to the result. According to the G6PD RDT result, primaquine will be prescribed at 0.25mg/kg/day for 14 days (normal patients) or 0.75mg/kg weekly for eight weeks (deficient patients). All will receive treatment with chloroquine to clear asexual stages of infection. Patients will be reviewed at day 2, day 7 and day 14. At these visits patients will undergo a brief clinical assessment and a small blood sample will be taken for repeat haemoglobin measurement and dried blood spot for carboxyprimaquine measurement (day 7 and day 14 only). In general, antimalarial treatment will be unsupervised to reflect field conditions. However a subset of 25 G6PD normal patients at a single site will have each day of their primaquine treatment administered and observed at the treatment centre. This is to determine a calibration curve for primaquine pharmacokinetic studies. Dried blood spots will be stored appropriately. Day zero samples will be genotyped in Bangkok (MORU, Dr. Mallika Imwong) after DNA extraction. PCR-RFLP will be used to detect the allele associated with the Mediterranean variant of G6PD deficiency. In addition DNA extracts will be sent for more systematic genetic testing for known G6PD variants through existing collaborations with the Wellcome Trust Sanger Institute. The day 7 and 14 dried blood spot samples will be analysed in the MORU pharmacology laboratory for primaquine and carboxyprimaquine concentrations, from which adherence to primaquine can be determined retrospectively, using the subset of 25 patients receiving directly observed therapy to calibrate the results. Funder: WellcomeTrust, Grant reference: 107548/Z/15/Z